{"nctId":"NCT01994993","briefTitle":"Antibiotic Safety (SCAMP)","startDateStruct":{"date":"2013-12"},"conditions":["Complicated Intra Abdominal Infections"],"count":260,"armGroups":[{"label":"Group 1 (ampicillin +gentamycin +metronidazole)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ampicillin and metronidazole and gentamicin"]},{"label":"Group 2 (ampicillin +gentamicin+clindamycin)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ampicillin and gentamicin and clindamycin"]},{"label":"Group 3 (piperacillin-tazobactam and gentamicin)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: gentamicin and Piperacillin- tazobactam"]},{"label":"Group 4 (metronidazole)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: standard of care antibiotics and metronidazole"]},{"label":"Group 5 (metronidazole/clindamycin/piperacillin-tazobactam)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: metronidazole, clindamycin, or piperacillin-tazobactam"]}],"interventions":[{"name":"ampicillin and metronidazole and gentamicin","otherNames":[]},{"name":"ampicillin and gentamicin and clindamycin","otherNames":[]},{"name":"gentamicin and Piperacillin- tazobactam","otherNames":[]},{"name":"standard of care antibiotics and metronidazole","otherNames":[]},{"name":"metronidazole, clindamycin, or piperacillin-tazobactam","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Informed consent obtained from parent(s) or legal guardian(s) (Groups 1-5)\n2. ≤33 weeks gestation at birth (Groups 1-3, 5)\n3. ≥34 weeks gestation at birth (Groups 4 and 5)\n4. PNA \\<121 days (Groups 1-5)\n5. Sufficient venous access to permit administration of study drug (intravenous \\[IV\\]) (Groups 1-5)\n6. Presenting physical, radiological, and/or bacteriological findings of a complicated intra-abdominal infection within 48 hours prior to randomization/first study drug dose (Groups 1-4)\\*\\*. Complicated intra-abdominal infections include secondary peritonitis, NEC grade II or higher by Bell's criteria, Hirschsprung's disease with perforation, spontaneous intestinal perforation, meconium ileus with perforation, bowel obstruction with perforation, gastroschisis with necrosis and/or perforation, omphalocele with necrosis and/or perforation, neonatal appendicitis, intestinal pneumatosis or portal venous gas, free peritoneal air on abdominal radiographic examination, or abdominal abscess.\n7. Suspected or confirmed infection for which the study drug may provide therapeutic benefit and planned CSF collection per standard of care (Group 5).\n\nExclusion Criteria\\*\n\n1. History of anaphylaxis in response to study drugs (Groups 1-5)\n2. Serum creatinine \\>2 mg/dL within 48 hours on measurement prior to and closest to randomization /first study drug dose (Groups 1- 5)\\*\\*\n3. Known ALT \\>250 U/L or AST \\>500 U/L on measurement closest to the time of randomization or first study drug dose (Groups 1-5)\\*\\*\n4. Any condition that, in the judgment of the investigator, precludes participation because it could affect participant safety (Groups 1-5)\n\n   * Do not apply for Group 5 participants receiving drug per standard of care\n\n     * Criteria must be satisfied by randomization (randomized Groups 1-3) or first study drug dose (non-randomized Groups 1-3, Group 4 and Group 5), whichever comes first.","healthyVolunteers":false,"sex":"ALL","maximumAge":"120 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Death","description":"Number of Participants who experienced Death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Therapeutic Success at Day 30","description":"Confirmed by 1).Alive, 2).Negative bacterial blood cultures, and 3). Clinical cure score \\>4.\n\nClinical cure score =1 for each of the following elements:\n\nFiO2 ≤ baseline FiO2; Urine output ≥1 mL/kg/h for 24-hour period prior to assessment; Absence of inotropic support at time of assessment; Absence of mechanical ventilation at time of assessment; No seizure in 24-hour period prior to assessment; pH ≥7.25 or not measured in 24 hours prior to assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"52","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Feeding Intolerance","description":"Feeding intolerance confirmed by documentation of any feedings held for \\>24 consecutive hours in infants being fed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Grade 3 and/or Grade 4 Intraventricular Hemorrhage (IVH)","description":"Grade 3 IVH: Subependymal hemorrhage with extension into lateral ventricles with ventricular enlargement\n\nGrade 4 IVH: Intraparenchymal hemorrhage","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Short Bowel Syndrome","description":"Short bowel syndrome: Operative reports documenting resection of bowel, estimated bowel length, and absence/presence of the ileocecal valve.\n\nTotal parenteral nutrition for \\>42 consecutive days after bowel resection, or a residual small bowel length of less than 25% expected for gestational age","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Intestinal Perforation","description":"Intestinal perforation: Radiological reports leading to the diagnosis of intestinal perforation. These include plain chest x-rays, plain abdominal x-rays, ultra-sonograms of the abdomen, contrast studies, and computed tomography scans of the abdomen and pelvis.\n\nOperative reports documenting surgical procedures leading to the diagnosis and/or treatment of intestinal perforation. These include placement of a surgical drain, laparotomy, intestinal resection, and ostomy placement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Intestinal Stricture","description":"Intestinal stricture: Radiology reports leading to the diagnosis of intestinal stricture. These include plain abdominal x-rays, upper gastrointestinal series with small bowel follow-through, contrast enema studies, and computed tomography scans of the abdomen and pelvis.\n\nOperative reports documenting surgical procedures leading to the diagnosis and/or treatment of intestinal stricture. These procedures include endoscopy, laparotomy, stricture dilatation, intestinal resection, and ostomy placement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Progressed to a Higher Stage of Necrotizing Enterocolitis (NEC), if NEC is the Cause of the Complicated Intra-abdominal Infection","description":"Progression is determined by the clinical NEC scoring","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Gastrointestinal Surgeries","description":"Determined by medical history and confirmed with hospital records. (Laparotomy)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Seizure","description":"documented seizure(s) in hospital records","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Positive Blood Cultures","description":"Positive blood culture (bacterial or fungal)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":62},"commonTop":["Thrombocytopenia","Anaemia","Jaundice cholestatic","Respiratory failure","Intraventricular haemorrhage neonatal"]}}}